Reshaping lipid metabolism with long-term alternate day feeding in type 2 diabetes mice
February 3, 2025 / Kdm2a Inhibitation / Skeletal Muscle Metabolism / Obesity / Insulin Resistance
A six-month alternate-day fasting regimen in type 2 diabetic (T2D) mice improved glucose homeostasis and liver lipid metabolism without weight loss. IF reduced liver fat, inflammation, and ceramide levels, enhanced insulin sensitivity, and altered gut microbiota favorably, suggesting metabolic benefits beyond weight reduction.
Improving insulin sensitivity with regular mango consumption
February 3, 2025 / Mango and Insulin Sensitivity / Glycemic Control / Natural Remedies
Regular mango consumption improved insulin sensitivity and glucose regulation in overweight and obese individuals without significantly affecting inflammation. After four weeks, fasting insulin, HOMA-IR, and pancreatic beta-cell function improved, suggesting mango’s potential role in glycemic control.
The Link Between Your Heart Health and MASH
January 31, 2025 / MASH / Heart Disease / Liver Fat / Metabolic Syndrome / Liver Health
Metabolic dysfunction–associated steatohepatitis (MASH) is linked to metabolic syndrome and heart disease. Excess liver fat worsens metabolic dysfunction, increasing cardiovascular risk. Lifestyle changes, routine screenings, and medications like GLP-1s and resmetirom can help manage MASH and improve heart and liver health.
Biomed Industries, Inc. Engages with Medicare to Advance Oral Bioglutide as an Affordable Metabolic Disorder Treatment
February 3, 2025 / Bioglutide Oral Obesity Treatment / Weight Loss / GLP-1 Alternative / Medicare Drug Price Negotiation / Metabolic Disorder Treatment
Biomed Industries is engaging with Medicare to advance Bioglutide™, an oral quadruple agonist for metabolic disorders. Bioglutide offers efficacy comparable to injectable GLP-1 therapies with fewer side effects and aims to provide a cost-effective, long-term obesity treatment.
Weight loss surgery may protect liver with MASH-related cirrhosis
Februrary 3, 2024 / Bariatric Surgery / MASH Cirrhosis / Weight Loss / Liver Health / Metabolic Surgery
Weight loss surgery significantly reduces the risk of serious liver complications in obese patients with MASH-related cirrhosis. The SPECCIAL study found bariatric surgery lowered progression to decompensated cirrhosis by 80%, suggesting it as a potential treatment option for liver disease management.
Single heat stroke exposure triggers long-term health risks and metabolic vulnerabilities
February 3, 2025 / Heat Stroke Long-term Effects / Metabolic Risks / Cardiac Hypertrophy
A single heat stroke exposure disrupts long-term metabolic regulation, increasing risks for cardiac hypertrophy, heart disease, and liver steatosis. EHS mice showed altered myocardial metabolism, elevated glycolysis markers, and diet-induced liver damage, highlighting heat illness as a trigger for chronic health disorders.
Regulation of adipocyte differentiation and lipid metabolism by novel synthetic chromenes exploring anti-obesity and broader therapeutic potential
February 3, 2025 / Synthetic Chromenes / Obesity / Novel Anti-Obesity Compounds / Weight Loss / Lipid Metabolism / Targeting Fat Cells for Obesity Treatment
Synthetic chromenes demonstrated anti-obesity potential by inhibiting adipogenesis and enhancing lipolysis in adipocytes. Select compounds reduced lipid accumulation, modulated key metabolic pathways, and showed promising pharmacokinetic profiles, suggesting their potential as novel therapeutic agents for obesity and related metabolic disorders.
Gut-derived sugars: A potential game-changer for weight management and diabetes
January 30, 2025 / Gut Microbiota / Metabolism / EPS for Weight Management / Probiotics / Metabolic Health / Diabetes Treatment
Gut microbiota-derived exopolysaccharides (EPS), particularly from Streptococcus salivarius, improve glucose metabolism, insulin sensitivity, and reduce inflammation. EPS supplementation in mice enhanced GLP-1 levels, SCFA production, and metabolic markers, suggesting potential for microbiota-targeted therapies in obesity and diabetes management.
Unlocking therapeutic potential of amlexanox in MASH with insights into bile acid metabolism and microbiome
February 1, 2025 / Amlexanox / MASH Treatment / Bile Acid Metabolism / Liver Health / Metabolic Disease / Hepatic Steatosis / Inflammation Therapy
Amlexanox significantly improves MASH by reducing hepatic steatosis, inflammation, and fibrosis while preventing disease progression to HCC. It enhances bile acid metabolism, lowers dyslipidemia, and reprograms gut microbiota, particularly increasing Akkermansia muciniphila, highlighting its potential as a metabolic and liver disease therapy.
Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs
Februrary 3, 2024 / Obesity Medication / GLP-1 Drugs / Weight Loss / Semaglutide and Tirzepatide Demand
Obesity medication prescriptions, particularly for semaglutide and tirzepatide, have surged alongside increasing online search interest. This study highlights the strong association between public awareness and prescription trends, suggesting real-time search data could help predict future obesity treatment demand.
From gut health to metabolism: How sleep controls more than you think
January 29, 2025 / Sleep / Metabolic Health / Sleep Apnea / Obesity Risk
This study links sleep quality to cardiovascular, metabolic, and immune health. Poor sleep increases risks for obesity, diabetes, inflammation, and osteoporosis. Sleep apnea severity correlates with visceral fat, highlighting the need for personalized sleep interventions to prevent chronic diseases.
Helicore enters obesity drugs arena with $65m funding round
January 29, 2025 / Helicore Obesity Drug Development / GIP Antagonists for Weight Loss
Helicore Biopharma raised $65M to develop GIP-neutralizing monoclonal antibodies for obesity treatment. Its lead candidate, HCR-188, aims to improve metabolic health by reducing GIP activity, enhancing leptin sensitivity, and promoting fat loss, with clinical trials expected in 2025.
New Study Links Cardiometabolic Index To Hypertension Risk
February 2, 2025 / Cardiometabolic Index / Hypertension / Heart Health / Visceral Fat / Bloos Pressure / Metabolic Dysfunction
A study using NHANES data links Cardiometabolic Index (CMI) to hypertension risk, showing CMI as a stronger predictor than BMI. Higher CMI correlates with visceral fat accumulation and metabolic dysfunction, particularly in women, highlighting its potential for cardiovascular risk assessment.
7 Things People With Diabetes Should Know About MASH
January 31, 2025 / MASH / Type 2 Diabetes / Liver Disease / Obesity / Liver Inflammation
People with type 2 diabetes have a higher risk of MASH, a progressive liver disease linked to insulin resistance and obesity. Early detection through routine screening is crucial, as MASH can sometimes be reversed with lifestyle changes and proper diabetes management.
Oral drug shows promise for severe fatty liver in Phase 2b trial
January 28, 2025 / Denifanstat / MASH Treatment / Fatty Acid Synthase Inhibitors / Oral Drug / Fatty Liver Disease
Denifanstat, a fatty acid synthase inhibitor, showed promise in a Phase 2b trial for MASH, significantly improving liver fat, inflammation, and fibrosis. The oral drug demonstrated favorable efficacy, though hair thinning was a notable side effect, warranting further Phase 3 trials.
Daily metformin prevents type 2 diabetes among patients with metabolic syndrome
January 30, 2025 / Metformin / Diabetetes Prevention / Mediterranean Diet / Metabolic Syndrome / Type 2 Diabetes Risk Reduction / Clinical Trial Results
Daily metformin (1,700 mg) significantly reduced type 2 diabetes incidence in patients with metabolic syndrome, with the greatest benefit seen when combined with a Mediterranean diet. However, metformin did not lower the risk of cardiovascular disease or cancer.
New endometrial cancer study highlights overlooked risk factors
January 31, 2025 / Metabolic Syndrome / Endometrial Cancer / Obesity / Cancer Prevention / Blood Sugar Control / Cancer Prevention
A study from Brunel University found that metabolic syndrome (MetS) increases endometrial cancer risk. Screening for MetS could help identify high-risk women, particularly those with obesity, and early interventions like weight loss or blood sugar control may reduce risk.
FDA approves new indication for Ozempic to lower kidney risks in type 2 diabetes, CKD
January 28, 2024 / Ozempic FDA Approval / CKD / Semaglutide / Kidney Disease / GLP-1 / Cardiovascular Health
The FDA approved semaglutide (Ozempic) to reduce kidney disease progression, kidney failure, and cardiovascular death in type 2 diabetes and CKD patients. The FLOW trial showed a 24% lower kidney disease risk, reinforcing its role in cardiometabolic and renal protection.
The Hidden Link Between Stress, Weight Gain and High Blood Pressure—And How to Fix It
February 1, 2024 / Stress / Metabolic Syndrome / Hypertension / Chronic Stress / Blood Pressure Control / Metabolic Health
Chronic stress contributes to metabolic syndrome, increasing the risk of hypertension, weight gain, and high blood sugar. Research suggests meditation, interval walking, and cold therapy can help regulate stress, lower inflammation, and improve metabolic health without medical intervention.